Tech Company Financing Transactions
RNAimmune Funding Round
On 8/25/2020, RNAimmune raised $2.4 million in Seed funding from Terra Magnum Capital Partners.
Transaction Overview
Company Name
Announced On
8/25/2020
Transaction Type
Venture Equity
Amount
$2,350,000
Round
Seed
Investors
Proceeds Purpose
The company will use the proceeds to advance its Covid-19 vaccine (RV1730) program and neoantigen-based cancer vaccine programs.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
401 Professional Dr. 280
Gaithersburg, MD 20879
USA
Gaithersburg, MD 20879
USA
Phone
Undisclosed
Website
Email Address
Overview
RNAimmune is a leading company in the field of messenger RNA (mRNA) technology with more than 20 years' expertise in handling and optimizing this versatile molecule for medical purposes.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Dong Shen
Chief Financial Officer
Nigel Yip
Chief Medical Officer
Kevin He
VP - Bus. Development
Stanley He
Browse more venture capital transactions:
Prev: 8/25/2020: Prelude Therapeutics venture capital transaction
Next: 8/25/2020: UserGuiding venture capital transaction
Share this article
Where The Data Comes From
We document every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs